1999
DOI: 10.1097/00002826-199903000-00007
|View full text |Cite
|
Sign up to set email alerts
|

Intravenous Loading of Valproate for Epilepsy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
22
0
1

Year Published

2002
2002
2017
2017

Publication Types

Select...
6
2
1

Relationship

0
9

Authors

Journals

citations
Cited by 42 publications
(24 citation statements)
references
References 0 publications
1
22
0
1
Order By: Relevance
“…6 Naritoku and Mueed gave infusions of IV valproate sodium at either 20 or 50 mg/min in 20 patients with epilepsy. 7 Three cases experienced notable side effects, each with vomiting, dizziness and nausea, and hypotension. 7 Venkataraman and Wheless studied 21 seizure patients with IV valproate sodium doses from 21 to 28 mg/kg at infusion rates of 3 or 6 mg/min.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…6 Naritoku and Mueed gave infusions of IV valproate sodium at either 20 or 50 mg/min in 20 patients with epilepsy. 7 Three cases experienced notable side effects, each with vomiting, dizziness and nausea, and hypotension. 7 Venkataraman and Wheless studied 21 seizure patients with IV valproate sodium doses from 21 to 28 mg/kg at infusion rates of 3 or 6 mg/min.…”
Section: Discussionmentioning
confidence: 99%
“…7 Three cases experienced notable side effects, each with vomiting, dizziness and nausea, and hypotension. 7 Venkataraman and Wheless studied 21 seizure patients with IV valproate sodium doses from 21 to 28 mg/kg at infusion rates of 3 or 6 mg/min. 8 No changes in blood pressure, electrocardiogram (ECG), or mental status were noted.…”
Section: Discussionmentioning
confidence: 99%
“…The delayed response might be explained by both the slightly lower loading dose and infusion rate (25 mg/kg in 100 mL saline in 15 min at a dose of 1.32-1.65 mg/kg/min), although plasma levels remained within range in all patients. In contrast with other reports [20][21][22], we adopted submaximal doses not only in accordance with the official recommendations of the Italian League Against Epilepsy [4] and the indications of the manufacturer, but also considering the clinical condition of our population, characterized by less severe forms of SE, as stated earlier (i.e. no ICU patients with GTCSE).…”
Section: Discussionmentioning
confidence: 99%
“…The use of VPA in patients with intracranial bleedings is questionable because of the various effects of VPA on platelet number and function as well as on several clotting factors [247,248]. But, in general, the safety of i/v VPA, even at high doses, fast infusion rates and in cardiac instable patients, was demonstrated in several studies [249][250][251][252][253][254][255][256][257][258][259]. However, prospective randomised well-(i.e.…”
Section: S C H W E I Z E R a R C H I V F ü R N E U R O L O G I E U N mentioning
confidence: 99%